Castle Biosciences SEC Filings

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported equity awards tied to performance. On January 12, 2026, she received 9,207 Performance-Based Stock Units (PSUs), each representing the right to one share of common stock at a price of $0. On the same date, 9,207 shares of common stock were acquired at $0 upon vesting of 50% of PSUs granted on March 4, 2024, after the board certified that performance criteria were met.

Following these transactions, she directly holds 21,530 shares of Castle Biosciences common stock and indirectly holds 97,251 shares through The Fritz Shorter Trust, where she and her spouse are trustees and beneficiaries. The reported PSUs represent the remaining 50% of the 2024 performance-based grant, which will vest only if additional milestones are achieved.

Castle Biosciences reported that Chief Commercial Officer Juvenal Tobin received common stock as performance-based compensation. On January 12, 2026, 9,207 Performance-Based Stock Units (PSUs) from a grant made on March 4, 2024 vested after the board certified that certain performance criteria were met.

Each PSU converts into one share of Castle Biosciences common stock, so 9,207 shares of common stock were acquired at a price of $0 per share. Following this transaction, Tobin beneficially owned 96,032 shares of common stock directly, and 9,207 PSUs remain outstanding, which will vest only if additional milestones are achieved.

Castle Biosciences Chief Financial Officer Frank Stokes reported equity awards tied to performance-based stock units. On 01/12/2026, 8,124 Performance-Based Stock Units (PSUs) granted on March 4, 2024 vested after the board certified that certain performance criteria were met, resulting in the acquisition of 8,124 shares of common stock at a price of $0 per share.

These vested PSUs represent 50% of the 2024 PSU grant. The remaining 50% of the 2024 PSUs, representing an additional 8,124 PSUs, will vest only if specified milestones are achieved. Following the transaction, Stokes beneficially owns 58,450 shares of common stock directly and 8,124 PSUs.

Castle Biosciences, Inc. reported that it has shared an early look at its recent business performance. On January 11, 2026, the company issued a press release with certain preliminary performance results for the fourth quarter of 2025 and for the full year ended December 31, 2025, which is provided as Exhibit 99.1.

The company also released an investor slide presentation on the same date, attached as Exhibit 99.2, which management may use in future meetings. Both the preliminary results and the slide presentation are being furnished under Items 2.02 and 7.01, respectively, and are expressly stated as not being deemed “filed” for purposes of the Exchange Act or incorporated by reference into other filings unless specifically referenced.

Castle Biosciences Inc. insider activity: President, Chief Executive Officer and director Derek J. Maetzold reported open-market sales of common stock under a Rule 10b5-1 trading plan adopted on May 8, 2025. He sold 2,678 shares on January 5, 2026 at a weighted-average price of $38.09 per share and 1,339 shares on January 6, 2026 at a weighted-average price of $40.096 per share, for a total of 4,017 shares sold.

After these transactions, Maetzold directly held 29,513 shares of common stock. He also reported indirect beneficial ownership through multiple trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust, 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust, several 2018 remainder trusts each holding 3,615 or 3,618 shares, and 85,959, 18,718 and 44,323 shares held by DJM Grantor Retained Annuity Trusts Nos. 5, 6 and 7, respectively.

Castle Biosciences Inc. reported insider stock sales by its president, chief executive officer and director. On 12/15/2025, the reporting person sold 18,513 shares of common stock at a weighted-average price of $38.747 and 1,012 shares at $39.304. On 12/16/2025, they sold an additional 12,821 shares at a weighted-average price of $38.554. These trades were made under a Rule 10b5-1 trading plan adopted on May 8, 2025. After the reported sales, the reporting person directly owns 34,869 shares of common stock and also has indirect beneficial ownership of multiple blocks of shares through several family and grantor retained annuity trusts.

Castle Biosciences’ chief commercial officer reported selling 13,200 shares of the company’s common stock on 12/11/2025 at a weighted-average price of $37.48 per share. The transaction is disclosed as a sale of non-derivative securities on a Form 4 filing.

Following this sale, the officer directly beneficially owns 86,825 shares of Castle Biosciences common stock. The filing notes that the transaction was executed in multiple trades at prices ranging from $37.31 to $37.72 per share, with the reported price reflecting the weighted-average sale price.

Castle Biosciences' chief financial officer reported an insider stock sale. On 12/11/2025, the officer sold 4,496 shares of common stock at $37.45 per share, leaving 50,326 shares owned directly after the transaction.

Castle Biosciences’ president, chief executive officer and director reported multiple stock transactions tied to restricted stock unit (RSU) vesting. On December 9, 2025, RSUs converted into 33,495 shares of common stock, followed by the disposition of 13,181 shares at $38.25 per share to cover tax obligations. On December 10, 2025, additional RSUs converted into 15,424 shares, with 6,070 shares disposed of at $38.02 per share for taxes, leaving 67,215 shares of common stock held directly.

The reporting person also lists indirect beneficial ownership in Castle Biosciences common stock through several family and grantor retained annuity trusts, each holding separate blocks of shares for the benefit of the reporting person, spouse and children.